Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

1 total trials 1 recruiting

Filter these 1 trials by phase, country, sponsor and more.

Open in Search →

Showing 1–1 of 1 trials